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544 The Journal of Thoracic and CardioObjective: The extraluminal technique of pulmonary artery banding can be difficult
to perform precisely in conjunction with cardiopulmonary bypass and is associated
with a significant risk of band-related complications. We analyzed our results with
an intraluminal technique of pulmonary artery banding in patients who required
cardiopulmonary bypass for the performance of associated cardiac repairs.
Methods: The medical records of 18 neonates and infants who underwent intralu-
minal pulmonary artery banding were retrospectively reviewed. A circular patch
with a 3.0-mm, 3.6-mm, or 4.0-mm diameter fenestration was sutured to the inner
circumference of the main pulmonary artery. Preoperative, intraoperative, and
postoperative variables were reviewed to assess the efficacy and safety of the
intraluminal technique.
Results: Intraluminal pulmonary artery banding produced a consistent and signifi-
cant reduction in the systolic pulmonary artery pressure (64.00  12.24 to 16.53 
6.33 mm Hg, P  .001), the systolic pulmonary artery pressure/systolic systemic
pressure ratio (0.91  0.10 to 0.19  0.07, P  .001), and the pulmonary
flow/systemic flow ratio (4.32  3.04 to 0.91  0.49, P  .015). There were no
band-related anatomic complications. Two patients did require percutaneous dila-
tion of the intraluminal pulmonary artery band before debanding to palliate systemic
arterial desaturation.
Conclusions: Intraluminal pulmonary artery banding is an effective palliative procedure
that can be used in patients who require cardiopulmonary bypass for the performance of
cardiac repairs in addition to placement of the pulmonary artery band.
Advances in the surgical repair of congenital cardiac defects haveresulted in a trend toward single-stage neonatal repairs and a reducedneed for initial palliative procedures. Despite this, there remain rareindications for the performance of palliative pulmonary artery band-ing (PAB). Extraluminal PAB (EL-PAB) can be associated withsignificant complications and is difficult to perform in conjunction
with cardiopulmonary bypass (CPB). When PAB is performed in conjunction with
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Dassociated procedures that require CPB, we find that intralu-
minal PAB (IL-PAB) is a reasonable alternative to EL-PAB
for consistently and reproducibly limiting pulmonary blood
flow with a low incidence of PAB-related complications.
Patients and Methods
Data Collection
The medical records of 18 neonates and infants with complex
congenital cardiac disease who underwent IL-PAB at Children’s
Hospital of Michigan from 1993 through 2003 were retrospec-
tively reviewed after obtaining institutional review board approval.
Preoperative, intraoperative, and postoperative variables from both
the banding and debanding procedures were collected.
Analysis
All data were entered and sorted in Microsoft Office Excel 2003
(Microsoft Corp, Redmond, Wash). These data were imported into
SPSS for Windows (version 11.5.0; SPSS Inc, Chicago, Ill) for
statistical analysis. Quantitative variables that approximated a nor-
mal distribution were reported as the mean  SD and were
analyzed by using the Student paired t test. Quantitative variables
that did not approximate a normal distribution were reported as the
median with a range and were analyzed by using the Wilcoxon
signed-rank test.
Demography
There were 10 (56%) boys and 8 (44%) girls with a mean age at
IL-PAB of 35  32 days. The mean weight of the study subjects
was 3.6  0.83 kg, with a body surface area of 0.22  0.03 m2.
Cardiac Diagnoses
The cardiac diagnoses of the study subjects were grouped into 3
broad categories: (1) single-ventricle variants with unrestricted
pulmonary blood flow and no evidence of systemic outflow tract
obstruction at the subaortic, aortic annular, or ascending aortic
levels (10 [56%] patients); (2) left dominant unbalanced complete
atrioventricular canal defects (LD-CAVCs) with unrestricted pul-
monary blood flow and questionable adequacy of the right ven-
tricular volume (4 [22%] patients); and (3) miscellaneous cardiac
defects with 2 balanced ventricles, unrestricted pulmonary blood
flow, and a prohibitively high risk for primary complete repair
because of severe associated cardiac defects and medical condi-
tions (4 [22%] patients). The decision to place patients with
LD-CAVCs in a category distinct from patients with an unequiv-
ocally univentricular heart was an arbitrary one. At the time of the
banding procedure, it was believed that some of the patients with
LD-CAVCs might eventually become candidates for a one-and-
two-thirds ventricle repair,1 as opposed to a complete Fontan
palliation.
Clinical Presentation
Before the IL-PAB, 14 (78%) patients were hospitalized, with 12
(67%) of these being critically ill in the intensive care unit.
Seventeen (94%) patients demonstrated symptoms consistent with
congestive heart failure, including failure to thrive (12 [67%]
patients) and tachypnea (11 [61%] patients). Six (33%) patients
The Journal of Thoracirequired preoperative mechanical ventilation. The median pre-
banding systemic saturation was 89% (range, 66%-100%).
IL-PAB Surgical Technique
The surgeries were performed by 3 pediatric cardiac surgeons over
the 10-year study period and represent all of the IL-PABs that have
been performed at this institution. Cardiac exposure was obtained
through a standard median sternotomy incision. The site for ve-
nous cannulation was chosen on the basis of the requirements for
performance of the associated cardiac repairs. Direct cannulation
of the superior and inferior venae cavae was performed if right
atrial exposure, right ventricular exposure, or both was necessary.
Otherwise, a single right atrial venous cannula was placed through
the right atrial appendage. Varying degrees of hypothermia with
reduced pump flow were used, as necessary, to optimize the
exposure for performance of the associated cardiac repairs.
The IL-PAB was typically constructed toward the end of the
operation during a rewarming period of full flow with a decom-
pressed and perfused heart. A transverse incision in the anterior
hemicircumference of the main pulmonary artery (MPA) 2 mm
above the pulmonary valve commissures and proximal to the left
and right branch pulmonary artery orifices was created. A circular
patch of glutaraldehyde-fixed bovine pericardium (Peri-Guard
Pericardium; Synovis Surgical Innovations, St Paul, Minn), pho-
Figure 1. A transverse incision is made in the anterior hemicir-
cumference of the MPA. The fenestrated circular patch is sutured
to the posterior wall of the MPA. The anterior MPA hemicircum-
ference is closed by sandwiching the remainder of the patch
between the edges of the MPA arteriotomy, thereby completing
the fixation of the IL-PAB.tofixed bovine pericardium (Sulzer Carbomedics Cardiofix Peri-
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Dcardium with Photofix Technology; Carbomedics Inc, Austin,
Tex), or polytetrafluoroethylene (PTFE; Gore-Tex Cardiovascular
Patch [0.6-mm thickness]; W. L. Gore & Associates, Inc, Newark,
Del). was constructed with a diameter equal to that of the MPA.
Care was taken to avoid significant oversizing of the diameter of
the patch to avoid bulging of the patch into the orifices of the left
or right branch pulmonary arteries. The patch was fenestrated with
a 2.7-mm (2.7-mm punch; Scanlan International, St Paul, Minn),
3.6-mm, or 4.0-mm (3.5-mm and 4.0-mm punch; Genzyme Corp,
Biosurgery, Fall River, Mass) circular punch, depending on the
patient’s weight and the judgment of the surgeon of record. In
general, a 3.6-mm aperture diameter (11 [61%] patients) was
chosen for patients weighing 3.0 to 3.5 kg. A 4-mm aperture
diameter was usually constructed for patients weighing greater
than 3.5 kg (5 [28%] patients). In 2 (11%) patients a 2.7-mm punch
hole was enlarged to a 3-mm diameter aperture. The posterior
hemicircumference of the fenestrated patch was then sutured to the
luminal surface of the posterior hemicircumference of the MPA at
a point opposite to the MPA by using a 5-0 or 6-0 Prolene
(Ethicon, Inc, Somerville, NJ) continuous suture. The anterior
hemicircumference of the patch was then sandwiched between the
edges of the transverse pulmonary arteriotomy by using the same
running suture. This closed the anterior pulmonary arteriotomy
while completing the intraluminal fixation of the PAB (Figure 1).
The patient was weaned from CPB on 100% inspired oxygen
and the inotropic support necessary to maintain an adequate car-
diac output and saturations. After the discontinuation of CPB, the
fraction of inspired oxygen was gradually reduced to maintain
arterial saturations of 70% to 80%. Modified ultrafiltration was
performed. The hemoglobin level was maintained in the range of
12 to 15 g/dL. Although the arterial saturations were frequently in
the 70% to 79% range in the early postoperative period, they
typically increased steadily over the ensuing 48 hours as the lungs
recovered from the adverse effects of CPB.
Associated Surgical Procedures
Associated surgical procedures requiring CPB were performed on
17 (94%) of the patients undergoing IL-PAB (Table 1). This
provided the opportunity to perform IL-PAB as a part of the
required CPB procedure. Exploratory cardiotomy to assess the
feasibility of primary repair was the sole CPB procedure per-
TABLE 1. Concomitant procedures performed with intralu-
minal pulmonary artery banding
No. Procedure
2 Atrial septectomy
4 Atrial septectomy; repair of hypoplastic arch; coarctation
repair
3 Repair of hypoplastic arch; coarctation repair
1 Repair of interrupted aortic arch
3 Repair of TAPVC
4 Exploratory cardiotomy
1 Exploratory cardiotomy; epicardial pacemaker insertion
TAPVC, Total anomalous pulmonary venous connection.formed in conjunction with IL-PAB in 5 (28%) patients.
546 The Journal of Thoracic and Cardiovascular Surgery ● MarPulmonary Artery Debanding Surgical Technique
During pulmonary artery debanding (PAD), the cannulation and
conduct of CPB was identical to that during the IL-PAB procedure.
When a cavopulmonary connection was performed in conjunction
with PAD, the MPA was divided at the band site. The pulmonary
valve leaflets and the proximal MPA stump were closed separately.
The distal MPA was closed primarily. When a 2-ventricle repair or
a one-and-two-thirds ventricle repair1 was performed at the time of
PAD, the transverse incision in the MPA was opened. The IL-PAB
was excised, and the MPA was closed with a longitudinal and
teardrop-shaped MPA patch extended into the anterior pulmonary
sinus.
Results
Prebanding Echocardiographic and
Catheterization Data
All patients had preoperative echocardiograms to document
the anatomy and to establish the presence of unrestricted
pulmonary blood flow. Eleven (61%) patients had a preop-
erative cardiac catheterization with cineangiograms to sup-
plement the echocardiographic data. The systolic pulmo-
nary artery pressure (S-PAP) in the catheterized group was
64  12 mm Hg, and the S-PAP/systolic systemic pressure
(SSP) ratio was 0.91  0.1. The pulmonary vascular resis-
tance (PVR) was 4.0 2.6 Woods units/m2, and the median
PVR to systemic vascular resistance (SVR) ratio was 0.25
(range, 0.10-0.58). The preoperative pulmonary flow/sys-
temic flow ratio (Qp/Qs) was 4.3  3.0.
IL-PAB Operative Data
The CPB time was 81 30 minutes, with a crossclamp time
of 32  22 minutes. The systemic saturation in the operat-
ing room at the end of the procedure was 80%  4%.
IL-PAB Hospital Course
The hospital mortality after IL-PAB and associated procedures
was 22% (4 patients) and was attributable to associated pro-
found medical problems. One patient with mitral atresia, ob-
structed total anomalous pulmonary venous connection, and
double-outlet right ventricle (DORV) was receiving preopera-
tive extracorporeal membrane oxygenation (ECMO) for pro-
found respiratory failure. Postoperatively, he was maintained
on ECMO for 10 days but was not able to be weaned because
of persistent low cardiac output and pulmonary parenchymal
disease. One patient with Down syndrome, LD-CAVC, coarc-
tation of the aorta, and hypoplastic aortic arch died postoper-
atively of respiratory syncytial pneumonia and bacterial sepsis.
One patient with a variant of hypoplastic left heart syndrome
(HLHS) and multiple ventricular septal defects (VSDs) was
given a preoperative diagnosis of anal atresia, necrotizing
enterocolitis, syndrome of inappropriate antidiuretic hormone,
renal failure, generalized hypotonia, and massive anasarca of
unknown cause. The patient died of overwhelming bacterial
sepsis and multisystem organ failure postoperatively. The final
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Dpatient was born at 33 weeks’ gestation with CAVC, DORV,
partial anomalous systemic venous connection, noncompacted
left ventricular myocardium, congenital heart block, polysple-
nia, and persistent metabolic acidosis. This patient died of
persistent low cardiac output postoperatively caused by preex-
isting myocardial dysfunction.
The discharge room air saturation of the hospital survi-
vors was 84%  9%. The echocardiographically estimated
IL-PAB gradient at hospital discharge was 65 14 mm Hg.
There was no evidence of pulmonary artery distortion, as
determined on the basis of the discharge echocardiogram.
The median length of stay of the 14 IL-PAB survivors was
8 days (range, 5-34 days).
Percutaneous Transcatheter Balloon Dilation of the
IL-PAB Orifice
Two (11%) patients underwent successful percutaneous
transcatheter balloon dilation of the IL-PAB aperture for
low arterial saturations.
One 3.5-kg patient with mitral atresia–DORV and a
4-mm IL-PAB fenestration underwent balloon dilation of
the IL-PAB aperture on postoperative day 3 after arterial
saturations in the 60% to 69% range on high inspired
fraction of inspired oxygen. He was extubated the following
day and was discharged home on postoperative day 8 with
room air saturations of 85%. When he returned for PAD and
a hemi-Fontan procedure 5 months later at 6 months of age,
his room air saturations and IL-PAB gradient were 79% and
59 mm Hg, respectively.
Another 4.5-kg patient with mitral atresia, DORV, and
coarctation of the aorta–hypoplastic aortic arch and a 4-mm
IL-PAB fenestration was discharged home with a room air
saturation of 80% and an IL-PAB gradient of 86 mm Hg.
She was readmitted 3 months postoperatively with room air
saturations of 70%. Rather than proceed directly to PAD
with the hemi-Fontan procedure, she underwent balloon
dilation of the IL-PAB aperture. Her room air arterial sat-
urations improved to 83% and remained stable until she
underwent an uneventful PAD and hemi-Fontan procedure
at 7 months of age.
Interval to Debanding (PAD)
Thirteen (93%) of the 14 IL-PAB survivors underwent
PAD. One patient was lost to follow-up. The median inter-
val from IL-PAB to PAD was 5.9 months (range, 3.7-12.4
months), and the mean age at PAD was 7.7  2.3 months.
The echocardiographically determined predebanding gradi-
ent was 82  15 mm Hg. All 13 patients underwent cardiac
catheterization with cineangiograms as a prelude to their
PAD procedure. The directly measured IL-PAB gradient of
the 13 catheterized patients who underwent PAD was 69 
17 mm Hg. Table 2 compares the prebanding S-PAP, S-
PAP/SSP ratio, PVR, PVR/SVR ratio, and Qp/Qs ratio of
the IL-PAB survivors who had a catheterization before the
The Journal of ThoraciIL-PAB with the same values in those patients who under-
went cardiac catheterization before their PAD. The IL-PAB
produced a durable reduction of the S-PAP (P  .001), the
S-PAP/SSP ratio (P  .001), and the Qp/Qs ratio (P 
.015). Although the decrease in PVR was not statistically
significant, the decrease in the PVR/SVR ratio did approach
statistical significance (P  .086).
PAD Procedure
None of the patients who survived to the debanding proce-
dure had any evidence of branch pulmonary artery distor-
tion or pulmonary valve damage related to the IL-PAB. In
all of the patients who underwent PAD, the MPA at the
band site demonstrated a relative constriction related to the
circumferential IL-PAB suture line and the fixed diameter
of the IL-PAB.
The hospital mortality for the debanding procedure was
15.4% (2 patients). One patient with LD-CAVC underwent
a hemi-Fontan procedure and died postoperatively of re-
peated bilateral branch pulmonary artery thromboses caused
by a hypercoagulable state. The remaining patient was born
weighing 2 kg with multiple VSDs, coarctation of the aorta,
and hypoplastic aortic arch. She underwent an initial repair
of coarctation of the aorta and hypoplastic aortic arch with
IL-PAB. At her debanding procedure, a perimembranous
VSD, a posterior muscular VSD, and an anterior muscular
VSD were closed with 3 separate large patches. The pul-
monary artery was debanded, and the main pulmonary ar-
tery was closed with a patch. She required postoperative
ECMO because of intrinsic left ventricular dysfunction and
died of persistent low cardiac output, despite maximal sup-
port.
Discussion
Extraluminal Technique of PAB
Coincident with advances in the early, complete, single-
stage repair of congenital cardiac defects, there are now
fewer indications for performing initial palliative proce-
TABLE 2. Prebanding and predebanding catheterization
data
Value Prebanding Predebanding P value
S-PAP (mm Hg) 64.00 12.24 16.53 6.33 .001*
S-PAP/SSP 0.91 0.10 0.19 0.07 .001*
PVR (WU/m2) 3.96 2.59 2.7 1.54 .520*
PVR/SVR 0.25 (0.10-0.58) 0.21 (0.08-0.32) .086†
Qp/Qs 4.32 3.04 0.91 0.49 .015*
S-PAP, Systolic pulmonary artery pressure; SSP, systolic systemic pres-
sure; PVR, pulmonary vascular resistance; SVR, systemic vascular resis-
tance; Qp/Qs, pulmonary to systemic flow ratio; WU, Wood units.
*Student paired t test (values expressed as means  SD).
†Wilcoxon signed-rank test (values expressed as median with a range).dures, such as PAB, than there were in the past.2 PAB was
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with excessive pulmonary blood flow caused by a VSD.
Since that time, many experimental and clinical techniques
for the performance of PAB have been described in the
literature. These proposed extraluminal techniques involve
wrapping the MPA with (1) prosthetic band material that
requires reoperation if postoperative adjustment is neces-
sary,4,5 (2) prosthetic material and devices that can be
adjusted percutaneously in the postoperative period,6-11 (3)
prosthetic material that can be balloon dilated in the post-
operative period,12-15 (4) devices that can be adjusted
remotely,16 and (5) absorbable prosthetic material.17-19
Intraluminal Technique of PAB
An intraluminal technique for performing PAB was first
described by Doty and colleagues20 in 1980 in a case report
describing a palliative procedure for HLHS. In 1981, Beh-
rendt and Rocchini21 described a similar technique for pal-
liation for HLHS by using a fenestrated flap of native
pulmonary artery to construct an intraluminal band within
the pulmonary artery. Young and associates,22 in 1989,
described the use of a fenestrated synthetic patch to con-
struct an IL-PAB for palliation of 2 patients with truncus
arteriosus. Parnell23 responded in the same year with a letter
to the editor describing his experience with an identical
technique used to successfully palliate a patient with truncus
arteriosus and tricuspid atresia. In 1999, Conte and cowork-
ers24 described the use of IL-PAB to successfully stage the
complete repair of a patient with transposition of the great
arteries, VSD, and a hypoplastic tricuspid valve and right
ventricle. This present report is, to our knowledge, the first
article to describe and analyze a series of patients with
IL-PAB.
Indications for PAB
Although modern indications for the use of either extralu-
minal or intraluminal PAB are controversial, clinical situa-
tions in which PAB might be appropriate include (1) Swiss-
cheese septum, (2) selected patients with multiple VSDs
(other than Swiss-cheese septum), (3) patients with single-
ventricle variants with unrestricted pulmonary blood flow
and no existing (or impending) subaortic obstruction, (4)
patients in need of left ventricular retraining, and (5) other
miscellaneous conditions. Furthermore, some patients with
congenital cardiac defects with excessive pulmonary blood
flow that might otherwise be amenable to early and com-
plete surgical repair might benefit from initial palliative
PAB because of the presence of associated severe medical
conditions that preclude safe primary repair. One such ex-
ample is a severely premature infant with hyaline membrane
disease, multiple VSDs, and ventilator dependency with
failure to thrive, despite medical management. Although
some indications still exist for the continued placement of
548 The Journal of Thoracic and Cardiovascular Surgery ● MarPABs, we believe that in general every effort should be
made to use the technique sparingly. When, however, place-
ment of a PAB is indicated in conjunction with the use of
CPB, IL-PAB is a dependable and predictable surgical
option.
Complications of PAB
In the present series of IL-PAB and in isolated case reports
of various permutations of IL-PAB,20-24 there have been no
anatomic complications attributable to the technique itself.
On the other hand, a wide variety of complications have
been reported with the use of EL-PAB techniques. Some of
these include (1) branch pulmonary artery distortion,5 (2)
erosion and migration of the band through the pulmonary
artery wall,25-27 (3) sterile and mycotic pulmonary artery
aneurysm formation at the band site,5,28 (4) pulmonary
artery thrombosis,29 (5) phrenic nerve palsy,5 and (6) vocal
cord paresis.5
None of the IL-PABs in this series required reinterven-
tion for tightening. On the other hand, 2 patients undergoing
IL-PAB did require percutaneous balloon dilation of the
band aperture to treat systemic arterial desaturation. There
were no complications related to these interventions.
Advantages of IL-PAB
Formulas for the placement of EL-PABs5 have proved help-
ful as starting points to estimate the appropriate initial band
circumference. However, these formulas are only guide-
lines, and because of anatomic variations of the MPA be-
tween individual patients, they do not produce predictable
MPA apertures. The EL-PAB circumference must be fre-
quently adjusted to achieve the desired clinical result. Even
after achieving an initially satisfactory result, there might be
a period of internal MPA remodeling or distal band migra-
tion after placement of an EL-PAB. This can lower the
initial EL-PAB gradient and necessitate reoperation to
tighten the band.5 Placement of an EL-PAB in patients who
have recently been weaned from CPB is especially prob-
lematic because the adverse effects of CPB on the pulmo-
nary vasculature and parenchyma are added to individual
patient variables to complicate the decision-making process
involved in the placement of a satisfactory EL-PAB.
The major advantage of IL-PAB is in its application to
situations in which CPB must be used for other cardiac
procedures. It produces a predictable and reproducible band
aperture, despite variations in patient anatomy and physiol-
ogy and without producing anatomic complications, such as
migration or internal remodeling, which might affect the
band gradient. Because IL-PAB is an open technique per-
formed with the pulmonary valve and branch pulmonary
artery orifices under direct vision, injury or distortion of the
pulmonary valve or branch pulmonary arteries is unlikely,
especially when compared with extraluminal techniques.
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ing on the patient’s size, have produced satisfactory dis-
charge band gradients (65  14 mm Hg) with room air
saturations of 84%  9%. These gradients have also been
stable over time (69  17 mm Hg, predebanding catheter-
ization gradient). IL-PAB has also produced a reliable and
durable reduction in the S-PAP, PAP/SSP ratio, and Qp/Qs
ratio, thereby protecting the pulmonary vasculature and
providing a satisfactory substrate for the performance of a
second-stage repair later in life. Although the decrease in
PVR has been less predictable, there is a trend toward
significance in the decrease of the PVR/SVR ratio. None of
the 2 deaths in the PAD group appeared to be related to
increased PVR. IL-PAB is also readily amenable to percu-
taneous balloon dilation for treatment of systemic arterial
desaturation should the IL-PAB aperture prove to be inad-
equate. This ability to percutaneously dilate the IL-PAB
aperture is a distinct advantage over the usual extraluminal
banding techniques.
Disadvantages of IL-PAB
Although IL-PAB is a more precise method for PAB, the
requirement for CPB is a significant disadvantage when
compared with EL-PAB. Although percutaneous balloon
dilation of a tight IL-PAB aperture is a straightforward and
effective advantage of this technique, tightening of an IL-
PAB aperture would be a more complex undertaking requir-
ing CPB. The intraluminal technique of PAB also increases
the duration of CPB beyond that required for performance
of the associated cardiac surgical procedures. Finally, there
is a theoretic possibility of bleeding from the IL-PAB suture
line in the MPA.
Conclusions
IL-PAB is precise, predictable, and effective as a palliative
procedure to limit pulmonary blood flow in patients who
require CPB for the performance of procedures additional to
the PAB. Given the low rate of IL-PAB–related complica-
tions and the reliability of the procedure, serious consider-
ation should be given to the use of this technique in pref-
erence to EL-PAB in patients requiring CPB.
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Discussion
Dr John Hawkins (Salt Lake City, Utah). I would like to com-
mend Dr Piluiko and his colleagues at the Children’s Hospital of
Michigan for thinking outside the box here and challenging us to
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Dbasically present a new look at a way to perform what is an old
procedure, namely PAB. I think, as Dr Shumway eloquently said
this morning, that the best way to predict the future is to invent it,
and therefore I always welcome articles that challenge our con-
ventional wisdom of the way we do things.
I would just like to point out, as the authors did in the article,
that this is actually a resurrection of an old technique on which one
of our former presidents, Don Dody, reported back in 1980, when
he discussed one of the very first successful neonatal palliations of
HLHS, proving once again that there really is nothing new under
the sun in cardiac surgery.
I think the authors have fulfilled the role of their title, namely
that they have proved that this is an efficacious technique in that it
decreased pulmonary artery pressure and Qp/Qs ratio and achieves
what they set out to do, but I would have to say I still need to be
convinced that this is something that we should be doing, and I
have 3 questions that will give you a chance to try to convince me.
First of all, 10 of your 18 patients had single-ventricle variants,
and 4 more had unbalanced forms of left ventricular dominant
atrioventricular canal. These are patients who would, at many
centers, be directed toward a Norwood type of procedure, at the
very least perhaps oversewing of the pulmonary valve and a shunt.
With the results for Norwood palliation in this day and age being
15% as a quite common mortality rate and in some centers even
5% or 10%, as we heard about this morning, an initial mortality
rate of 22% and then a debanding mortality of 15% seems rela-
tively high. How would you convince us that we should do what
seems like a relatively risky procedure for a single-ventricle pa-
tient rather than perhaps in some centers performing a lower-risk
Norwood palliation? I will let you answer these one at a time.
Dr Piluiko. Thank you, Dr Hawkins. None of the patients in
the single-ventricle variant or unbalanced atrioventricular canal
groups required a first-stage Norwood or Damus-Kaye-Stansel
type of palliation because all of these patients had an adequate
subaortic area, nonstenotic aortic valve leaflets, adequate aortic
annular diameters, and adequate dimensions of the ascending
aorta. As you mentioned, though, some of these patients could
have been appropriately palliated by suturing closed the pulmo-
nary valve leaflets and ligating or dividing the pulmonary artery
with placement of a systemic-to-pulmonary artery shunt. It is not
known whether this type of palliation is superior to PAB. As we
will outline in detail in the article, we do not believe that the
mortality in this series was related to the banding or debanding
procedures per se but rather was clearly associated with pro-
foundly serious associated medical and cardiac conditions that
would predict a poor surgical outcome, regardless of the palliative
scheme chosen.
Dr Hawkins. My second question is as follows. In Dr Doty’s
original article, the thing that got that particular patient in trouble
was fibrointimal proliferation at the aperture of the fenestration in
this internal band. Two of your patients required balloon dilation
for cyanosis postoperatively, and therefore my question is this: At
the time of reoperation for debanding, did you see any type of this
fibrointimal proliferation in any of the 3 different types of mate-
rials that you used for the internal PAB?
Dr Piluiko. We did not see significant luminal fibrointimal
growth at the debanding procedure in any of our patients. Given
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PAB prosthetic surface, irrespective of whether it is constructed of
bovine pericardium or PTFE. However, for the period during
which our IL-PABs were in place, this problem was not encoun-
tered.
Dr Hawkins. But even with the PTFE you did not see fibrointi-
mal proliferation around this hole?
Dr Piluiko. For the time that these bands were in place, we did
not see any significant fibrointimal growth in the lumen of the
IL-PABs.
Dr Hawkins. One last quick question before we end here. I
guess I would have to be a little bit cautious about adopting this,
at least for me. I think some of the risks that you state are true for
extraluminal PAB, mainly that it is difficult to adjust the band after
bypass in those rare patients that need this. My question is, how do
you adjust this after you have started bypass? If it is too much or
too tight of a band or too loose of a band, it seems to me it would
require CPB to make an adjustment, and some of the things that
you say are the disadvantages of extraluminal banding are even
more true for this.
Dr Piluiko. After placement of an IL-PAB, our patients are
initially fairly cyanotic in the operating room. None of our pa-
tients, however, had to be placed back on bypass to either tighten
or loosen the band acutely. Typically, the patient’ saturations
would increase gradually in the operating room and in the subse-
quent 1 or 2 postoperative days until they reached satisfactory
discharge levels. In the one case in which a patient’s saturation did
not improve in the first few postoperative days, we successfully
ballooned the band orifice. The other patient who, 3 months after
banding, experienced a decrease in these saturations before the
time at which we were comfortable performing a hemi-Fontan
procedure also underwent a successful ballooning. We view the
ability to loosen a tight IL-PAB nonoperatively as a virtue of this
technique rather than a liability. None of our IL-PABs were loose,
either acutely or remotely. Again, we view this consistent creation
of an appropriately tight band as an asset of the technique. If,
however, an IL-PAB did appear to be too loose and require
tightening, this would require bypass to perform accurately. This
would have to be considered a rare but theoretically plausible
liability inherent in the IL-PAB technique. When compared with
the many well-documented complications that can plague IL-
PABs, we believe that the risk/benefit ratio of the intraluminal
technique favors it over the extraluminal technique in cases in
which bypass must be used for the performance of associated
cardiac surgical procedures.
Dr Winfield Wells. (Los Angeles, Calif). I just want to really
make more of a brief comment than ask a question. I think much
of the problems with bands that you have reported took place when
the banding material might not have been as ideally selected as it
can be now. Actually, in using a silicone rubber material for a
band, our experience is that the patients can be banded for 6
months or whenever you usually get to the next palliation for
single ventricle and that the band can be slipped off and no
augmentation of the pulmonary artery needs to be done. I would
just comment that some of the new external banding materials in
fact overcome many of the obstacles you have mentioned.Dr Piluiko. Thank you for your comment.
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